DISCOUNT ZERTIFIKAT - ASTRAZENECA | Market Closed - Boerse Frankfurt Warrants 16:20:30 17/05/2024 BST | ||
| 103.2 EUR | +0.18% |
|
| Current month | +0.18% | ||
| 1 month | +2.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 103.2 | +0.18% |
| 16/05/24 | 103 | -0.01% |
| 15/05/24 | 103 | +0.19% |
| 14/05/24 | 102.8 | -0.06% |
| 13/05/24 | 102.9 | +0.11% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 04:20 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
BNP Paribas
|
| WKN | PC3VY7 |
| ISIN | DE000PC3VY76 |
| Date issued | 25/01/2024 |
| Maturity | 20/06/2025 (397 Days) |
| Parity | 1 : 1 |
| Emission price | 97.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 103.2 € |
|---|---|
| Lowest since issue | 96.36 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.7
USD
Spread / Average Target
+9.02%
- Stock Market
- Certificates
- Certificat
